Psoriatic arthritis (PsA), a progressive and erosive joint disease associated with significant functional impairment, reduced health-related quality of life, and serious clinical and economic burdens, is a common comorbidity in patients with psoriasis (PsO). An early, aggressive approach to treatment with systemic agents or biologics is recommended; however, lack of or loss of efficacy can occur and many patients often report dissatisfaction with treatment. Thus, the need for additional therapies remains. Advances in understanding the pathogenesis of PsO/PsA have revealed novel treatment targets. Subsequently, new and emerging agents targeting Janus kinases and IL-23/IL-17 cytokines are being added to the PsA treatment armamentarium or are under clinical investigation. This session will address the barriers to optimal treatment, explore the PsA inflammatory cascade and identification of novel treatment targets, and review latest data on new and emerging PsA treatments including JAK, IL-17, and IL-23 agents and how to incorporate them into treat-to-target strategies.